Skip to main content

Table 1 Demographics and baseline laboratory markers of training cohort and test cohort

From: Sparse logistic regression revealed the associations between HBV PreS quasispecies and hepatocellular carcinoma

  Training cohort Test cohort
CHB (n = 63) HCC (n = 46) CHB (n = 41) HCC (n = 71)
Gender
Female 21 (33.3%) 6 (13.6%) 18 (43.9%) 13 (18.3%)
Male 42 (66.7%) 38 (86.4%) 22 (53.7%) 58 (81.7%)
Age 36.6 ± 13.8 52.4 ± 8.3 40.1 ± 11.9 51.1 ± 10.2
Serum HBV DNA 7.48 5.02 6.24 5.32
(log10 IU/ml) (6.50–7.83) (4.43–6.25) (4.89–7.65) (4.80–5.85)
TBIL (μmol/L) 13 14.2 11 14.5
  (10.0–17.0) (11.1–19.8) (8.7–15.7) (11.5–19.4)
DBIL (μmol/L) 3 5.5 4 5.7
  (3.0–5.0) (4.0–7.7) (3.0–6.0) (4.4–7.5)
TP (g/L) 74 68.8 75 67.8
  (71.5–79.0) (64.4–71.1) (70.0–78.0) (64.1–72.7)
ALB (g/L) 45.5 39.8 45 40.9
  (41.0–49.7) (37.0–42.5) (43.0–48.5) (38.0–43.9)
ALT (U/L) 38 43.4 51 40.5
  (19.0–66.0) (24.7–78.4) (29.5–77.0) (33.0–71.0)
AST (U/L) 30 46 33 40
  (21.0–45.0) (25.0–84.5) (26.5–54.2) (31.0–64.0)
GGT (U/L) 22 81 24 78
  (15.0–51.0) (41.3–156.0) (18.0–43.2) (50.0–121.5)
ALP (U/L) 71.5 92 72 92
  (59.299.7) (69.25–131.5) (56.0–82.5) (73.5–112.0)
HBsAb
Negative 17 (40.5%) 36 (85.7%) 38 (97.4%) 64 (95.5%)
Postive 25 (59.5%) 6 (14.3%) 1 (2.6%) 3 (4.5%)
HBeAg
Negative 31 (73.8%) 25 (59.5%) 8 (20.5%) 41 (61.2%)
Postive 11 (26.2%) 17 (40.5%) 31 (79.5%) 26 (38.8%)
HBeAb
Negative 33 (78.6%) 10 (23.8%) 31 (79.5%) 18 (26.9%)
Postive 9 (21.4%) 32 (76.2%) 8 (20.5%) 49 (73.1%)
HBV genotype
B 26(41.2%) 8(17.4%) 15(36.6%) 12(16.9%)
C 37(58.7%) 36(78.3%) 26(63.4%) 59(83.1%)
Tumor size(cm)   5.6(3.32–9.40)   11(7.8–14.5)
Capsule  
Intact   5 (11.4%)   10 (15.6%)
None   5 (11.4%)   11 (17.2%)
Partial   34 (77.3%)   43 (67.2%)
Tumor number
1   32 (72.7%)   58 (90.6%)
2   0 (0.0%)   3 (4.7%)
3   12 (27.3%)   3 (4.7%)
PVTT
None   23 (52.3%)   45(63.3%)
Yes   21 (47.7%)   19 (29.7%)
AFP(ng/ml)   565 (29.1–15,375.0)   187 (7.83–1210.0)
  1. AFP Alpha-fetoprotein, ALB Albumin, ALP Alkaline phosphatase, ALT Alanine aminotransferase AST Aspartate aminotransferase CHB Chronic hepatitis B, DBIL Direct bilirubin, GGT γ-glutamyltransferase; HBV Hepatitis B virus, HBeAg Hepatitis B e antigen, HBeAb Hepatitis B e antibody, HBsAb Hepatitis B antibody, HCC Hepatocellular carcinoma, TBIL Total bilirubin, TP Total protein, PVTT Portal veint umor thrombus